Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release. The H.C. Wainwright BioConnect Investor Conference will take place on May 20, 2025, at the Nasdaq Headquarters in New York City. About Akebia Therapeutics CAMBRIDGE, Mass., May ...